Palisade Bio (PALI) Retained Earnings (2010 - 2026)
Palisade Bio (PALI) reported Retained Earnings of -$162.3 million for Q1 2026, down 17.48% year-over-year from -$196.7 million in Q1 2025, and down 6.29% quarter-over-quarter from -$152.7 million in Q4 2025.
Palisade Bio (PALI) Retained Earnings (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has 17 years of Retained Earnings data on file, last reported at -$162.3 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$162.3 million, down 17.48% year-over-year; the trailing twelve-month figure through Mar 2026 was -$162.3 million (down 17.48% YoY), and the FY2025 annual result was -$152.7 million, down 12.34% from the prior year.
- Retained Earnings eased to -$162.3 million in Q1 2026 per PALI's latest filing, from -$152.7 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$98.8 million in Q1 2022 and troughed at -$162.3 million in Q1 2026.
- A 5-year average of -$126.0 million and a median of -$125.0 million in 2024 frame the typical range for Retained Earnings.
- On a YoY basis, Retained Earnings climbed as much as 2.52% in 2022 and fell as far as 3560670.89% in 2022.
- A 5-year view of Retained Earnings shows it stood at -$109.2 million in 2022, then decreased by 11.28% to -$121.5 million in 2023, then slipped by 11.88% to -$135.9 million in 2024, then slipped by 12.34% to -$152.7 million in 2025, then fell by 6.29% to -$162.3 million in 2026.
- Business Quant data shows PALI's Retained Earnings at -$162.3 million in Q1 2026, -$152.7 million in Q4 2025, and -$143.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -838.07 Mn |
| 10 | Palisade Bio | 357.48 Mn | 227.91 Mn | - | -162.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -162.33 Mn |
| Dec 31, 2025 | -152.73 Mn |
| Sep 30, 2025 | -143.83 Mn |
| Jun 30, 2025 | -140.96 Mn |
| Mar 31, 2025 | -138.17 Mn |
| Dec 31, 2024 | -135.94 Mn |
| Sep 30, 2024 | -132.60 Mn |
| Jun 30, 2024 | -129.11 Mn |
| Mar 31, 2024 | -125.03 Mn |
| Dec 31, 2023 | -121.51 Mn |
| Sep 30, 2023 | -118.54 Mn |
| Jun 30, 2023 | -114.92 Mn |
| Mar 31, 2023 | -111.53 Mn |
| Dec 31, 2022 | -109.19 Mn |
| Sep 30, 2022 | -105.18 Mn |
| Jun 30, 2022 | -101.19 Mn |
| Mar 31, 2022 | -98.85 Mn |
| Dec 31, 2021 | -94.64 Mn |
| Sep 30, 2021 | -95.72 Mn |
| Jun 30, 2021 | -103.80 Mn |